Until the early 2000s, screening of LS was done by focusing on cancer patients with high‐risk conditions according to the Amsterdam II criteria or revised Bethesda guideline;28 and MMR IHC and MSI analysis were then conduced on these selected patients.2, 34, 36 Later, universal screening using MMR IHC7, 45 and/or MSI analysis36, 46 (±age limitation) prevailed over these demographic selections. Here, MRC1 is linked to cancer.